Royal Bank of Canada Reiterates Outperform Rating for Aardvark Therapeutics (NASDAQ:AARD)
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Royal Bank of Canada in a note issued to investors on Tuesday,Benzinga reports. They presently have a $21.00 price objective on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 124.60% from […]
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Royal Bank of Canada in a note issued to investors on Tuesday,Benzinga reports. They presently have a $21.00 price objective on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 124.60% from […]
